电子健康干预同时发生的高风险饮酒和抑郁症状:随机对照试验的覆盖范围,坚持和两年效应
D Guertler1, S Baumann2, A Moehring3
1Institute for Community Medicine, Department of Prevention Research and Social Medicine, University Medicine Greifswald, Greifswald, Germany; DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Germany; Institute for Community Medicine, Department of Methods in Community Medicine, University Medicine Greifswald, Greifswald, Germany.
这项研究发现,针对高风险的酒精使用和抑郁症的主动电子健康干预具有很高的坚持性,但效果很小,不显著. 需要进一步的研究来探索重大抑郁症对潜在效果的改变.
科学领域:
- 数字健康干预措施 数字健康干预措施
- 心理健康研究 心理健康研究
- 药物使用障碍 药物使用障碍
背景情况:
- 同时发生的高风险酒精使用和抑郁症状很普遍.
- 积极的电子健康干预措施为治疗提供了潜在的途径.
- 了解影响范围,坚持和长期影响至关重要.
研究的目的:
- 评估主动电子健康干预 (ITE) 对同时发生的高风险酒精使用和抑郁症状的两年影响.
- 评估ITE的覆盖率和坚持率.
- 为了确定干预效应的潜在调节者.
主要方法:
- 一项随机对照试验,涉及德国医疗保健患者,他们接受了风险酒精使用和低值抑郁症的查.
- 参与者在六个月内收到了个性化的反信和每周的短信.
- 主要结局是酒精使用和抑郁症状的综合测量,评估时间为6,12和24个月.
主要成果:
- 51%的符合条件的患者同意参与;40%被随机分配到ITE组.
- 73%的ITE参与者完成了所有干预组件.
- 隐性变化模型显示,在6,12和24个月后,对复合措施的干预效应很小,不显著.
结论:
- 电子健康干预显示了很高的坚持,但产生了小的,不显著的效果,长达12个月.
- 一个趋势表明,基线主要抑郁症可能会改变潜在效果,这需要进一步调查.
- 限制包括自我报告的结果和未知的心理治疗状态.
更多相关视频
08:05A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers
Published on: January 5, 2018
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
相关概念视频
Depressive Disorders: MDD and Dysthymia
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Depression: Overview
Long-term Depression
Calcium Ion Concentration Mechanism
If over...
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
